2022
DOI: 10.1080/17425255.2022.2117606
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 149 publications
0
1
0
Order By: Relevance
“…LEV and brivaracetam (BRV) primarily act by binding SV2A [ 58 ]. LEV is a broad-spectrum ASM, that is effective in both focal and primary generalized seizures [ 58 ]. Its partial effectiveness on absences has been described in Section 3.2.2 .…”
Section: Mechanisms Of Actionmentioning
confidence: 99%
“…LEV and brivaracetam (BRV) primarily act by binding SV2A [ 58 ]. LEV is a broad-spectrum ASM, that is effective in both focal and primary generalized seizures [ 58 ]. Its partial effectiveness on absences has been described in Section 3.2.2 .…”
Section: Mechanisms Of Actionmentioning
confidence: 99%